KR960003729A - 항과혈당증 작용을 지닌 약제 - Google Patents

항과혈당증 작용을 지닌 약제 Download PDF

Info

Publication number
KR960003729A
KR960003729A KR1019950012695A KR19950012695A KR960003729A KR 960003729 A KR960003729 A KR 960003729A KR 1019950012695 A KR1019950012695 A KR 1019950012695A KR 19950012695 A KR19950012695 A KR 19950012695A KR 960003729 A KR960003729 A KR 960003729A
Authority
KR
South Korea
Prior art keywords
pharmaceutical
drugs
acid addition
physiologically acceptable
acceptable acid
Prior art date
Application number
KR1019950012695A
Other languages
English (en)
Other versions
KR100366130B1 (ko
Inventor
칸 엘베르트
지글러 디이터
브뢰크너 라인하르트
Original Assignee
닥터 디이터 라우어
칼리-케미 파마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닥터 디이터 라우어, 칼리-케미 파마 게엠베하 filed Critical 닥터 디이터 라우어
Publication of KR960003729A publication Critical patent/KR960003729A/ko
Application granted granted Critical
Publication of KR100366130B1 publication Critical patent/KR100366130B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)

Abstract

본 발명은 과혈당중의 치료 및/또는 예방에 사용되는 약제학적 제제를 제조하기 위한 목소니딘과 이의 생리학적으로 허용가능한 산부가염들의 이용에 관한 것이다.

Description

항과혈당증 작용을 지닌 약제
내용없음

Claims (2)

  1. 과열당중의 치료를 위한 약제학적 제제를 제조하기 위한 용도의 Ⅰ의 4－클로로－5－〔(4,5－디하이드로－1H－이미다졸－2－일)－아미노〕－6－메톡시－2－메틸피리미딘 및 이의 생리학적으로 허용 가능한 산부가염들.
  2. 제1항에 따른 일반식 I 화합물 또는 이의 생리학적으로 허용 가능한 산부가염들의 항과혈당증 유효량을 일반적인 약제학적 보조제와 함께 적절한 약제학적 형태로 만드는 것을 특징으로 하는 과혈당증 치료용 약제학적 제제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950012695A 1994-07-01 1995-05-20 항과혈당증작용을지닌약제 KR100366130B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4423177.6 1994-07-01
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel

Publications (2)

Publication Number Publication Date
KR960003729A true KR960003729A (ko) 1996-02-23
KR100366130B1 KR100366130B1 (ko) 2003-03-26

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950012695A KR100366130B1 (ko) 1994-07-01 1995-05-20 항과혈당증작용을지닌약제

Country Status (23)

Country Link
US (1) US5712283A (ko)
EP (1) EP0689837B1 (ko)
JP (1) JP3841846B2 (ko)
KR (1) KR100366130B1 (ko)
CN (1) CN1092961C (ko)
AT (1) ATE210444T1 (ko)
AU (1) AU691580B2 (ko)
CA (1) CA2152998C (ko)
CZ (1) CZ287563B6 (ko)
DE (2) DE4423177A1 (ko)
DK (1) DK0689837T3 (ko)
DZ (1) DZ1894A1 (ko)
ES (1) ES2167385T3 (ko)
FI (1) FI117374B (ko)
HU (1) HU226946B1 (ko)
IL (1) IL113411A (ko)
NO (1) NO307029B1 (ko)
NZ (1) NZ270990A (ko)
PT (1) PT689837E (ko)
RU (1) RU2145857C1 (ko)
SK (1) SK282227B6 (ko)
UA (1) UA27954C2 (ko)
ZA (1) ZA954691B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980702511A (ko) * 1995-02-28 1998-07-15 크라우더 티 알 아테롬성 동맥경화증을 치료하기 위한 목소니딘의 용도
TR199802496T2 (xx) * 1996-06-06 1999-02-22 Eli Lilly And Company Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
IL123232A0 (en) * 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
AU9692898A (en) * 1997-10-17 1999-05-10 Eli Lilly And Company Potentiation of pharmaceuticals
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
WO2000044355A1 (en) * 1999-01-29 2000-08-03 Eli Lilly And Company Moxonidine salts
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
PL372695A1 (en) * 2002-06-19 2005-07-25 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
ZA200601804B (en) * 2003-10-10 2007-05-30 Solvay Pharm Gmbh Pharmaceutcal composition comprising a selective II imidazoline receptor agonist and an angiotensin II receptor blocker
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
FI953256A (fi) 1996-01-02
CZ287563B6 (en) 2000-12-13
RU2145857C1 (ru) 2000-02-27
CZ139395A3 (en) 1996-01-17
US5712283A (en) 1998-01-27
EP0689837B1 (de) 2001-12-12
FI117374B (fi) 2006-09-29
PT689837E (pt) 2002-04-29
DE4423177A1 (de) 1996-01-04
CA2152998A1 (en) 1996-01-02
SK74995A3 (en) 1996-05-08
ES2167385T3 (es) 2002-05-16
IL113411A0 (en) 1995-07-31
DE59509928D1 (de) 2002-01-24
IL113411A (en) 1999-07-14
AU1775795A (en) 1996-01-18
HUT72599A (en) 1996-05-28
CN1092961C (zh) 2002-10-23
JP3841846B2 (ja) 2006-11-08
ZA954691B (en) 1996-01-29
NO952624D0 (no) 1995-06-30
CA2152998C (en) 2002-09-03
EP0689837A2 (de) 1996-01-03
SK282227B6 (sk) 2001-12-03
CN1122224A (zh) 1996-05-15
UA27954C2 (uk) 2000-10-16
HU9501900D0 (en) 1995-08-28
DK0689837T3 (da) 2002-03-11
DZ1894A1 (fr) 2002-02-17
JPH0840906A (ja) 1996-02-13
NZ270990A (en) 1997-06-24
AU691580B2 (en) 1998-05-21
NO952624L (no) 1996-01-02
NO307029B1 (no) 2000-01-31
KR100366130B1 (ko) 2003-03-26
FI953256A0 (fi) 1995-06-30
EP0689837A3 (de) 1996-06-05
ATE210444T1 (de) 2001-12-15
HU226946B1 (en) 2010-03-29

Similar Documents

Publication Publication Date Title
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
SE8406538D0 (sv) Novel derivatives of purine
KR960003729A (ko) 항과혈당증 작용을 지닌 약제
KR920004391A (ko) 치환된 카복실산의 코데인 염, 이의 제조방법, 이의 용도 및 약제학적 조성물
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR900014406A (ko) 세펨 화합물 및 이의 제조방법
RU95109157A (ru) Противогипергликемически эффективная фармацевтическая композиция
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
KR900701278A (ko) 바이러스 감염 치료용 담즙산
EP0030023A3 (en) A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine
RU98101105A (ru) Новое применение в медицинских целях
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
KR920703060A (ko) 제약학적 배합물
KR870007098A (ko) 플루오르화 디아미노알킨유도체 및 이의 제조방법
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제
KR880001630A (ko) 5-플루오로우라실 유도체 및 그의 용도
US5093348A (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
KR880006198A (ko) 2,6-디아미노-3- 할로벤질피리딘, 이의 제조방법 및 이의 약제학적 용도
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR900013959A (ko) γ-카르블린 또는 그들의 제약학적으로 허용 가능한 산부가염 및/또는 수화물, 및 그들로 구성되는 제약학적 조성물
KR890002058A (ko) 간질 및 불안 상태의 예방 및 치료용 2,4,6-트리스-3-급-부틸아미노-1,-3,-5-트리아진
KR880011077A (ko) 유효치료 물질로서 사용하기 위한 tert- 부틸아미노-3(페닐-2'-펜옥시)-1-프로판올-2 및 그의 산부가염

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121129

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20131129

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee